StemoniX Announces Addition to Board of Directors

Company Announces Appointment of John Fletcher

MAPLE GROVE, MN, October 19, 2020 – StemoniX, Inc. is pleased to announce the  appointment of Mr. R. John Fletcher to the Company’s Board of Directors. Mr. Fletcher brings  more than 30 years of strategy and financing experience across the Pharmaceutical and  Healthcare Industry to the Board. He is currently Managing Partner of Fletcher Spaght  Ventures, a venture capital fund, and the founder and CEO of Fletcher Spaght, Inc., a  consulting firm that he founded in 1983 to provide growth-focused strategy assistance to client  companies.  

Mr. Fletcher’s current and past board experience spans public and private companies including  Alimed, AutoImmune, Axcelis, Fischer Imaging, GlycoFi, NMT Medical, Panacos  Pharmaceuticals, Quick Study Radiology and Spectranetics in addition to many academic and  non-profit institutions. Notable milestones include the $2B and $400M acquisitions by Fortune 500 companies of Spectranetics and GlycoFi, respectively, as well as being awarded the  National Association of Corporate Directors (NACD) Director of the Year Award in 2018, specifically for his unparalleled work at Spectranetics. 

He is a graduate of Southern Illinois University (MBA), Central Michigan University (Master’s  Degree in International Finance), and George Washington University (BA) and has served as an  instructor in International Business at the Warton School as well as a Captain and jet pilot in the  United States Air Force. 

Ping Yeh, StemoniX CEO and co-founder said, “John is a world-class Board and corporate  governance professional with a track record of successful ventures and deep knowledge of  drug discovery and development. We are thrilled to have his expertise on our Board of  Directors to guide us in our transformation of how drugs are developed.” 

StemoniX recently announced a definitive agreement to merge with Cancer Genetics, Inc. (Nasdaq: CGIX) to span the drug development process from early stage through pre-clinical.  The merger is expected to be completed before the end of 2020 and that Mr. Fletcher will be  elected to the CGIX Board as a StemoniX-nominated director. 

“StemoniX is at an exciting junction,” stated Mr. Fletcher. “The technology pioneered by  StemoniX and its ease of use is inspiring. Furthermore, their upcoming merger with CGIX will  lead the way toward cures for many diseases affecting both children and adults. I’m extremely  honored to take on this position – especially at this time.”  

ABOUT STEMONIX, INC.

StemoniX is empowering the discovery of new medicines through  the convergence of novel human biology and software technologies. StemoniX develops and 

manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural  and cardiac screening platforms for drug discovery and development. Predictive, accurate, and  consistent, these human models enable scientists to quickly and economically conduct research  with improved outcomes in a simplified workflow. Through collaborations with drug discovery  organizations, StemoniX tests compounds in-house, creates new cell-based disease models,  and operationalizes custom human iPSC disease models at large scale for high-throughput  screening. With leading-edge iPSC technologies and data science, StemoniX is helping global  institutions bring the most promising medicines to patients. To learn more about how  StemoniX products and services are accelerating discoveries, please visit www.StemoniX.com. 

Forward Looking Statement: This press release contains forward-looking statements for  purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). StemoniX, Inc.’s  disclaims any intent or obligation to update these forward-looking statements and claims the  protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of  such statements include, but are not limited to, statements relating to StemoniX, Inc.’s research  activities, expectations of current and future board member activities, future financial and/or  operating results, and potential for our services, future revenues or growth. Any statements  that are not historical fact (including, but not limited to, statements that contain words such as  “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to  be forward-looking statements. Forward-looking statements involve risks and uncertainties.  Such statements are based on current expectations, but actual results may differ due to a  variety of risks and uncertainties.  

Investor Contact:  

Ping Yeh, CEO 

StemoniX, Inc. 

Email: ping.yeh@stemonix.com 

Phone: (612) 807-9889

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER